It has indicated that statins during and after adjuvant chemotherapy in patients with colorectal cancer have been shown not to improve DFS, recurrence-free survival, and OS in KRAS mutant and wild-type patients [42]. This evidence concerns the gene KRAS and colorectal cancer.